Associated Papers
Breast Cancer Susceptibility: Meta-Analysis of Cytochrome P450 2C19 (CYP2C19) and Estrogen Receptor-1 (ESR1) Genetic Variants.
Shibi Anilkumar A et al.
Cancer Investigation, 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Structural pharmacogenomics of drug-associated SNPs in oral squamous cell carcinoma.
Sunil P et al.
Frontiers in Genetics, 2026
Cellular heterogeneity and therapeutic response profiling of human IDH + glioma stem cell cultures.
Chambwe N et al.
Scientific Reports, 2025
The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.
Obradovic J et al.
Molecular Biology Reports, 2025
BRAF mutations and targeted therapy in unclassified pericytic tumors: insights from genetic analysis and clinical response.
Golan H et al.
Bmc Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.
Nawab F et al.
Bmc Cancer, 2025
Cellular heterogeneity and therapeutic response profiling of human IDH+ glioma stem cell cultures.
Chambwe N et al.
Biorxiv : the Preprint Server for Biology, 2025
Precision proteogenomics reveals pan-cancer impact of germline variants.
Martins Rodrigues F et al.
Cell, 2025
Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting Partner.
Erdemir F et al.
International Journal of Molecular Sciences, 2025
Integrating functional proteomics and next generation sequencing reveals potential therapeutic targets for Taiwanese breast cancer.
Ku WC et al.
Clinical Proteomics, 2025
Investigation of Exome-Wide Tumor Heterogeneity on Colorectal Tissue-Based Single Cells.
Szakállas N et al.
International Journal of Molecular Sciences, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
Case Report: Recognition and management of SMARCA4-deficient renal cell carcinoma.
Wang W et al.
Frontiers in Oncology, 2025
Identification of novel germline and somatic mutations associated with hepatocellular carcinoma by next-generation sequencing.
Laaribi AB et al.
Frontiers in Pharmacology, 2025
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Villa M et al.
British Journal of Cancer, 2024
Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways.
Taniguchi-Ponciano K et al.
Acta Neuropathologica Communications, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
Park C et al.
Cancer Immunology, Immunotherapy : Cii, 2024
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
Auberle C et al.
Journal of Thoracic Disease, 2024
Associations between Radiomics and Genomics in Non-Small Cell Lung Cancer Utilizing Computed Tomography and Next-Generation Sequencing: An Exploratory Study.
Ottaiano A et al.
Genes, 2024
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I et al.
Journal of Translational Medicine, 2024
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
Aleksakhina SN et al.
International Journal of Molecular Sciences, 2024
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Versluis JM et al.
Cancer Immunology, Immunotherapy : Cii, 2024
Assessment of HER1 (rs11543848) and HER2 (rs1136201) polymorphism and their association with colorectal cancer susceptibility in Khyber Pakhtunkhwa, Pakistan.
Ullah A et al.
Molecular Biology Reports, 2023
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Sather CL et al.
Cancer Medicine, 2023
Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
Pipek O et al.
International Journal of Molecular Sciences, 2023
Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation.
Orzan F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Whole exome analysis reveals the genomic profiling related to chemo-resistance in Chinese population with limited-disease small cell lung cancer.
Yu J et al.
Cancer Medicine, 2023
Preliminary Experience of Liquid Biopsy in Lung Cancer Compared to Conventional Assessment: Light and Shadows.
Montella M et al.
Journal of Personalized Medicine, 2022
Two independent variants of epidermal growth factor receptor associated with risk of glioma in a Korean population.
Baek IK et al.
Scientific Reports, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Soria-Bretones I et al.
Science Advances, 2022
Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs).
Marinović S et al.
Cancer Genetics, 2022
Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Sohn SH et al.
Cancers, 2022
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors-Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
Alen BO et al.
Cancers, 2022
Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers.
Bignucolo A et al.
Expert Review of Clinical Pharmacology, 2022
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
Tsukahara S et al.
Scientific Reports, 2022
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Cserepes M et al.
Cancers, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2022
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A et al.
Targeted Oncology, 2022
The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.
Andonegui-Elguera S et al.
International Journal of Molecular Sciences, 2022
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma.
Sigala S et al.
Cells, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022